Case 2: Cisplatin-Ineligible Metastatic Bladder Cancer
EXPERT PERSPECTIVE VIRTUAL TUMOR BOARD
Arlene O. Siefker-Radtke, MD:I’d like to move on to case number 2, which is a 68-year-old Caucasian man who was referred to urology after an evaluation for gross hematuria. As anticipated in most bladder cancer patients, he has a past history of hypertension and COPD [chronic obstructive pulmonary disease] from smoking with a 30-year smoking history. He has a cystoscopy from one of D. Brown’s colleagues showing a nodular 8 cm mass at the left urethral orifice. And on transurethral resection, has a high-grade urothelial carcinoma invading into the muscularis propria. His PD-L1 [programmed death-ligand 1] score by CPS [combined positive score] was greater than 10.
However, on imaging, we had some unfortunate news where he had both enlarged pelvic lymph nodes and lung metastases. A bone scan was negative, but his creatinine clearance calculated by Cockcroft-Gault was about 42 mL/minute. So he’s now been diagnosed with a metastatic bladder cancer with borderline or poor kidney function.
Transcript edited for clarity.
FDA Accepts IND for UGN-103 in Low-Grade Intermediate-Risk NMIBC
April 15th 2024An investigational new drug application for UGN-103 was accepted by the FDA. A phase 3 study to assess the safety and efficacy of the agent in low-grade intermediate-risk non-muscle invasive bladder cancer is anticipated.
Read More
Study Shows Desire for Bladder-Sparing Treatments in High-Risk NMIBC
April 2nd 2024In an interview with Targeted Oncology, Joseph M. Jacob, MD, discussed how bladder preservation is the top reason for refusal of radical cystectomy in the TAR-200 monotherapy cohort of the SunRISe-1 study.
Read More
